Table 2 Patient characteristics
Group F (n = 31) | Group L (n = 47) | p value | |
|---|---|---|---|
Age (years) | 72.0 ± 9.3 | 74.6 ± 8.8 | 0.22 |
Male | 26 (83.9%) | 32 (68.1%) | 0.19 |
Body mass index (kg/m2) | 23.8 ± 3.4 | 24.3 ± 3.6 | 0.50 |
Hypertension | 25 (80.6%) | 44 (93.6%) | 0.14 |
Diabetes mellitus | 9 (29.0%) | 18 (38.3%) | 0.47 |
Current smoking | 0 (0%) | 2 (4.3%) | 0.52 |
Daily alcohol drinking | 12 (38.7%) | 13 (27.7%) | 0.33 |
Coronary artery disease | 26 (83.9%) | 43 (91.5%) | 0.47 |
Prior percutaneous coronary intervention | 25 (80.6%) | 39 (83.0%) | 1.0 |
Prior coronary bypass surgery | 1 (3.2%) | 2 (4.3%) | 1.0 |
Prior stroke | 4 (12.9%) | 4 (8.5%) | 0.71 |
Atrial fibrillation | 6 (19.4%) | 7 (14.9%) | 0.76 |
History of gastroduodenal ulcer | 5 (16.1%) | 9 (19.1%) | 0.77 |
History of eradication of H. pylori | 3 (9.7%) | 5 (10.6%) | 1.0 |
Gastrointestinal symptom rating scale | |||
Reflux symptom score | 1.4 ± 0.6 | 1.3 ± 0.6 | 0.19 |
Abdominal pain score | 1.4 ± 0.7 | 1.2 ± 0.5 | 0.32 |
Indigestion score | 1.4 ± 0.6 | 1.6 ± 0.6 | 0.24 |
Positive urinary H. pylori antibodies | 15 (48.4%) | 22 (46.8%) | 1.0 |
Duration of lansoprazole or famotidine treatment | 0.76 | ||
<1 year | 7 (14.9%) | 6 (19.4%) | |
≥1 year(s) | 40 (85.1%) | 25 (80.6%) | |
Dose of aspirin | 1.0 | ||
81 mg/day | 1 (3.2%) | 2 (4.3%) | |
100 mg/day | 30 (96.8%) | 45 (95.7%) | |
Type of aspirin | 1.0 | ||
Enteric-coated formulation | 30 (96.8%) | 45 (95.7%) | |
Buffered formulation | 1 (3.2%) | 2 (4.3%) | |
Other antiplatelet agents | 12 (38.7%) | 17 (36.2%) | 1.0 |
Warfarin | 8 (25.8%) | 8 (17.0%) | 0.40 |
Dabigatran | 2 (7.4%) | 2 (4.3%) | 0.62 |
Nitrates | 10 (32.3%) | 16 (34.0%) | 1.0 |
Calcium antagonists | 14 (45.2%) | 26 (55.3%) | 0.49 |
Angiotensin-converting enzyme inhibitors | 3 (9.7%) | 4 (8.5%) | 1.0 |
Angiotensin receptor blockers | 14 (45.2%) | 30 (63.8%) | 0.16 |
Statins | 27 (87.1%) | 42 (89.4%) | 1.0 |